BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Micvotabart pelidotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Micvotabart pelidotin\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05720117-10913@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Micvotabart pelidotin: Phase 1 readout est. (NCT05720117)
DESCRIPTION:Micvotabart pelidotin\, phase 1\, Solid Tumors.\nStudy: A Study
  of PYX-201 in Advanced Solid Tumors\nEstimated primary completion: 25 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/micvotabart-
 pelidotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05720117
URL:https://assetmemo.bio/drug/micvotabart-pelidotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06795412-10913@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Micvotabart pelidotin: Phase 1/2 readout est. (NCT06795412)
DESCRIPTION:Micvotabart pelidotin\, phase 1/2\, Solid Tumors.\nStudy: Phase
  1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid 
 Tumors\nEstimated primary completion: 6 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/micvotabart-pelidotin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06795412
URL:https://assetmemo.bio/drug/micvotabart-pelidotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
